Is Adipose Tissue a Reservoir for SARS-Cov2 Spread in Covid-19 Patients? (TA/SARS-Cov2)
June 26, 2024 updated by: Centre Hospitalier Universitaire de Nice
Is Adipose Tissue a Reservoir for SARS-Cov2 Spread?
Resident cells of human adipose tissue express ACE2 and DPP4, receptors for SARS-Cov2.
The hypothesis is that the virus may enter and spread in fat depots.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nice, France, 06000
- Chu De Nice
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female ≥ 18 years old
- Patients testing positive for Covid19
- Patients affiliated to social security
- Signing of free and informed consent
Exclusion Criteria:
- Vulnerable persons (- minors,
- adults under guardianship or curatorship,
- pregnant women,
- persons deprived of their liberty,
- persons who do not master the French language)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: patients with Covid-19
|
Two 4mm punch biopsies of subcutaneous abdominal or thight adipose tissue
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The presence of SARS-CoV2 in adipose tissue of Covid19 patients
Time Frame: Day 0
|
RT-qPCR for SARS-Cov-2 from RNAs and by immunodetection
|
Day 0
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The expression of inflammatory cytokines in adipose tissue of Covid19 patients
Time Frame: Day 0
|
RT-qPCR for IL6
|
Day 0
|
|
The expression of inflammatory cytokines in adipose tissue of Covid19 patients
Time Frame: Day 0
|
RT-qPCR for IL1
|
Day 0
|
|
The expression of inflammatory cytokines in adipose tissue of Covid19 patients
Time Frame: Day 0
|
RT-qPCR for TNFa
|
Day 0
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 3, 2020
Primary Completion (Actual)
September 9, 2020
Study Completion (Actual)
September 9, 2020
Study Registration Dates
First Submitted
June 10, 2020
First Submitted That Met QC Criteria
June 11, 2020
First Posted (Actual)
June 11, 2020
Study Record Updates
Last Update Posted (Actual)
June 27, 2024
Last Update Submitted That Met QC Criteria
June 26, 2024
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-PP-15
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.